Business Context and Reporting Period
Company: Ionis Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Context: The filing announces preliminary U.S. net product sales for the product TRYNGOLZA for the full year 2025.
Key Financial Metrics
- Revenue: Preliminary U.S. net product sales for TRYNGOLZA in 2025 were $105 million.
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics. This report focuses solely on preliminary product sales.
Material Changes
The filing does not provide comparative data for the prior period (2024) or year-over-year growth rates. It only states the absolute preliminary sales figure for 2025.
Guidance, Outlook, and Management Commentary
- Status of Data: The reported financial results are unaudited, subject to adjustment, and provided as an approximation.
- Future Reporting: Complete financial results are expected to be announced in February 2026.
- Legal Disclaimer: The information in this Item 2.02 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the final audited 2025 financial results when announced in February 2026.
- Confirm if the $105 million figure represents total company revenue or solely TRYNGOLZA sales (filing indicates solely TRYNGOLZA).
- Review the full press release (Exhibit 99.1) for additional context on sales drivers or market conditions.